Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A
J Clin Oncol. 2013 31 (14): 1767-74

PMID: 23569304 · DOI:10.1200/JCO.2012.44.7888

MeSH Terms (29)

Administration, Oral Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents Apoptosis Cell Cycle Cell Proliferation Disease Progression Drug Resistance, Neoplasm Female GTP Phosphohydrolases Humans Immunohistochemistry Indoles Male MAP Kinase Kinase 1 MAP Kinase Signaling System Melanoma Membrane Proteins Middle Aged Mitogen-Activated Protein Kinase Kinases Point Mutation Proto-Oncogene Proteins B-raf Skin Neoplasms Sulfonamides Tumor Cells, Cultured Vemurafenib

Connections (2)

This publication is referenced by other Labnodes entities: